2nd Feb 2022 08:36
Spectral MD Holdings Ltd - London and Dallas, Texas-based predictive analytics for wound care - Expects annual loss before interest, tax, depreciation, and amortization to be "materially" narrower than current market expectations, while cash position as at December 31 was "marginally" ahead of expectations. Explains this with lower costs per subject associated with its diabetic foot ulcer clinical training study. Grant revenue from its Biomedical Advanced Research & Development Authority funding contract for the burn indication is expected to be "broadly" in line with market expectations. Will release 2021 results by the end of March.
"Spectral continues to make good progress on its clinical and regulatory pathway, and the company is on track to deliver on its expected milestones notwithstanding the continued challenges of the Covid pandemic," Chief Executive Wensheng Fan says.
Current stock price: 35.90 pence
12-month change: down 29% from 59p listing price in June last year
By Abby Amoakuh; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
SMD.L